Besim Ogretmen to Doxorubicin
This is a "connection" page, showing publications Besim Ogretmen has written about Doxorubicin.
Connection Strength
0.685
-
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
Score: 0.348
-
Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene. 1997 Jan 30; 14(4):499-506.
Score: 0.127
-
Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther. 2007 Feb; 6(2):712-22.
Score: 0.064
-
Proteinase-3, a serine protease which mediates doxorubicin-induced apoptosis in the HL-60 leukemia cell line, is downregulated in its doxorubicin-resistant variant. Oncogene. 2002 Aug 01; 21(33):5160-74.
Score: 0.047
-
Dependence of ABCB1 transporter expression and function on distinct sphingolipids generated by ceramide synthases-2 and -6 in chemoresistant renal cancer. J Biol Chem. 2022 02; 298(2):101492.
Score: 0.045
-
Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance. Biochemistry. 1998 Aug 18; 37(33):11679-91.
Score: 0.035
-
Direct binding of glyceraldehyde 3-phosphate dehydrogenase to telomeric DNA protects telomeres against chemotherapy-induced rapid degradation. J Mol Biol. 2009 Dec 11; 394(4):789-803.
Score: 0.019